Topic: mergers and acquisitions
Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.
The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.
Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.
After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.
Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.
Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.
Invitae aims to expand its genetic counseling reach through the $50 million acquisition of Clear Genetics, developers of digital chatbot software.
WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.
Corindus Vascular Robotics reported that it has completed its first machine-assisted brain surgery procedure in humans.
After two years, the Federal Trade Commission has ordered the German prosthetics company Ottobock to roll back its acquisition of Freedom Innovations.
